PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of neoplasiaGuide for AuthorsAbout this journalExplore this journalNeoplasia (New York, N.Y.)
 
Neoplasia. 2010 June; 12(6): 485–498.
PMCID: PMC2887089

Cathepsin B Is the Driving Force of Esophageal Cell Invasion in a Fibroblast-Dependent Manner1

Abstract

Esophageal cancer, which frequently exhibits coordinated loss of E-cadherin (Ecad) and transforming growth factor β (TGFβ) receptor II (TβRII), has a high mortality rate. In a three-dimensional organotypic culture model system, esophageal keratinocytes expressing dominant-negative mutant versions of both Ecad and TβRII (ECdnT) invade into the underlying matrix embedded with fibroblasts. We also find that cathepsin B induction is necessary for fibroblast-mediated invasion. Furthermore, the ECdnT cells in this physiological context activate fibroblasts through the secretion of TGFβ1, which, in turn, is activated by cathepsin B. These results suggest that the interplay between the epithelial compartment and the surrounding microenvironment is crucial to invasion into the extracellular matrix.

Introduction

Esophageal cancer carries one of the worst mortality rates of any cancer. The prognosis for patients with esophageal squamous cell cancer remains poor because of the high rate of local and distant metastases at the time of diagnosis [1]. Critical oncogenes involved in the pathogenesis of esophageal squamous cell cancer include cyclin D1 and epidermal growth factor receptor (EGFR), and key tumor suppressor genes are TP53, E-cadherin, and TβRII. We previously developed and characterized an organotypic culture model focusing on p53 mutation in concert with EGFR overexpression, thus leading to the activation of stromal fibroblasts and matrix metalloprotease-mediated degradation of the extracellular matrix [2]. To evaluate other critical genetic events that are evident in esophageal tumorigenesis, we focus here on the coordinated loss of E-cadherin (Ecad) and TGFβ receptor type II (TβRII) and elucidate their functional consequences.

Loss of Ecad expression is prominent in epithelial-mesenchymal transition; therefore, Ecad has emerged as one of the “caretakers” of the epithelial phenotype [3]. The precise mechanism that underlies suppression of cell invasion as mediated by Ecad is not well established. One possibility is that the adhesive function of Ecad prevents cells from dissociating from each other and migrating into adjacent tissues [4,5]. Alternatively, Ecad binds and sequesters β-catenin at the cell membrane, which regulates the cytoplasmic pool of β-catenin and, therefore, represents a key mediator in the Wnt signaling pathway [6]. This function of Ecad is supported by studies in Drosophila and Xenopus embryos [7–9], which demonstrate that the formation of the cadherin-catenin complex antagonizes β-catenin signaling function, for example, during axis formation.

TβRII loss in cancer has been modeled in mice through a dominant negative approach in skin [10] and mammary glands [11] as well as conditional knock-out in the mammary glands [12]. In these models, mice develop tumors and have a high potential for metastasis, thereby supporting the tumor-suppressive function of TβRII and intact transforming growth factor β (TGFβ) signaling. This is supported further by the restoration of wild-type TβRII in colon and breast cancer cells that lack a functional TGFBR2 allele [13] and by the overexpression in thyroid carcinomas [14], in which the expression of TβRII conferred growth inhibition, suppressed anchorage independence, and abolished tumor formation in nude mice.

In a previous study, we demonstrated the importance of Ecad and TβRII in esophageal squamous cell cancer because 70% of patient tumors had coordinated loss of both proteins [15]. To identify the biological consequences, we have established an organotypic culture model mimicking the loss of Ecad and TβRII function through the expression of dominant-negative mutants of both proteins lacking the cytoplasmic tail in each case. We demonstrate here that esophageal cell invasion is initiated by the epithelial loss of Ecad and TβRII and is mediated further through cathepsin B induction resulting in increased levels of TGFβ1.

Materials and Methods

Cell Culture

Primary esophageal epithelial cells (keratinocytes) from normal human esophagus were established as described previously [15]. Cells were cultured at 37°C and 5% CO2 in keratinocyte serum-free medium (kSFM) supplemented with 40 µg/ml bovine pituitary extract, 1.0 ng/ml epidermal growth factor, 100 U/ml penicillin, and 100 µg/ml streptomycin (Gibco, Invitrogen, Carlsbad, CA). Fetal esophageal fibroblasts were grown in Dulbecco's modified Eagle medium (DMEM) with 10% FBS (Hyclone; Thermo Fisher Scientific, Waltham, MA), 100 U/ml penicillin, and 100 µg/ml streptomycin (Gibco, Invitrogen). Conditioned media were collected from both esophageal keratinocytes in kSFM and DMEM and fibroblasts in DMEM with 10% FBS after 72 hours. pGIPZ-shRNAmir constructs against cathepsin B were from Openbiosystems (Huntsville, AL; available through the VanderbiltMicroarray Shared Resource): shRNA#1 corresponds to clone V2LHS151050 with the following sequence: TGCTGTTGACAGTGAGCGAGGTGACAATGGCTTCTTTAAATA GTGAAGCCACAGATGTATTTAAAGAAGCCATTGTCACCCTGCCTACTGCCTCGGA, shRNA#2 is clone V2LHS151051. The sequence is TGCTGTTGACAGT GAGCGAGCACCGATCAGTACTGGGAAATAGTGAAGCCACAGATGTATTTCCCAGTACTTC GGTGCGTGCCTACTGCCTCGGA. As a control, the sequence-scrambled, nonsilencing pGIPZ vector provided by Openbiosystems was expressed.

Tissue Microarrays

The AccuMax Array (ISU ABXIS, Co, Seoul, South Korea) contains 80 esophageal squamous cancer tissues and four normal controls and is distributed by Accurate Chemical & Scientific Corp (Westbury, NY). Immunofluorescence staining was performed using anti-cathepsin B antibody and was scored on a scale from 1 to 4, with 1 being absent and 4 being the highest signal intensity. These scores were compared with scores from a previous study [15] on a serial section of the same tissue microarray analyzing the expression of Ecad and TβRII. Scores were plotted, and linear regression was calculated using Prism4 (GraphPad Software, Inc, La Jolla, CA). For the statistical analysis of the negative correlation, we used Spearman correlation.

Organotypic Culture

Organotypic cultures were grown as described previously [16]. In brief, human esophageal epithelial cells (keratinocytes) were seeded on day 7 onto a 3:1 collagen I/Matrigel layer with 7.5 x 104 human fetal esophageal fibroblasts embedded, after the matrix had contracted under the influence of the fibroblasts. Collagen I was purchased from Organogenesis (Canton, MA), and Matrigel Matrix was purchased from BD Biosciences (Franklin Lakes, NJ). On day 11, cultures were raised to an air-liquid interface to induce differentiation of the epithelium. Cultures were harvested on day 15, fixed in 10% formaldehyde (Fisher, Pittsburgh, PA), and later paraffin-embedded or directly embedded into OCT for frozen sections. Conditioned media were collected at the time of harvesting 72 hours after the last medium change and were either used immediately or snap-frozen and stored at -80°C. For analysis of the invading areas, ImageJ (NIH, Bethesda, MD) was used to select areas of invasion and to measure the surface area for graphic presentation.

Coculture and Transwell Assays

For the coculture, the matrix was prepared as for organotypic cultures with and without fibroblasts and plated into four-well chamber slides (Falcon, New Brunswick, NJ). The next day, the dominantnegative mutant versions of both Ecad and TβRII (ECdnT) cells were plated onto the matrices. In transwell experiments, the bottom chamber contained fibroblasts, fibroblast-conditioned medium, and DMEM as control. The transwell insert (pore size, 0.4 µm) was coated with matrix components as previously mentioned, and ECdnT cells were plated. All of the cocultures were incubated overnight. After the methanol/acetone fixation, immunofluorescence staining was performed with anti-cathepsin B, and nuclear counterstain using propidium iodide was performed.

Soft Agar Assay

Soft agar assays were performed as described by Hatziapostolou et al. [17]. In brief, a 1.5-ml lower layer of 1% agar in 1x DMEM/kSFM was placed into each well of a six-well culture plate and was allowed to solidify at room temperature. ECdnT cells, fibroblasts, or cocultures of both (2.5 x 104 cells total/well) were suspended in a plating layer of 0.67% agarose in 1 ml of conditioned medium from ECdnT cultures, organotypic cultures, fibroblast cultures, or control kSFM. The agar was allowed to solidify before incubating the plates at 37°C in a 5% CO2 humidified incubator for 2 weeks. The cells were fed every 48 hours using the appropriate conditioned medium. Colonies were counted and visualized using the Oxford Optronix Gel Count with the Gel Count Software, version 1.3 (Oxford, UK), and statistical significance was determined using the Student's t test.

Cell Invasion Assays

Invasion assays were as previously described [15] done using either 8-µm pore size Biocoat Matrigel invasion chambers or Fluoroblok invasion chambers (BD Biosciences). Inserts were placed in a 24-well plate containing kSFM, including all supplements or DMEM with 10% FBS as a control for the conditioned medium in the lower chamber. Conditioned media were collected from fibroblasts growing in DMEM 10% FBS for 72 hours. Cells (5 x 104 per chamber) were resuspended in starvation medium and added into each insert. After overnight incubation, the cells attached to the upper side of the membrane were removed gently, if necessary, and rinsed. Invading cells were stained with hematoxylin and eosin for quantification or with calcein AM (Molecular Probes, Invitrogen) as a fluorescent dye to count invading cells using a fluorometer (Multimode Plate Reader Synergy HT; Bio-Tek, Winooski, VT). All experiments were done at least in triplicate, and data are presented as mean ±SD. Student's t test was performed for statistical analysis.

Immunohistochemistry/Immunofluorescence

Immunohistochemistry was performed with the Vecta Elite Kit (Vector Laboratories, Burlingame, CA) following the manufacturer's protocol. Briefly, paraffin sections were treated with xylene and then boiled for 10 minutes in 10 mM citric acid buffer. Endogenous peroxidases were quenched using hydrogen peroxide before the sections were blocked in avidin D-blocking reagent and biotin-blocking reagent. The sections were incubated with primary antibody overnight at 4°C and secondary antibody for 30 minutes at 37°C, and then the signal was developed using the DAB substrate kit for peroxidase (Vector Laboratories). For immunofluorescence staining, a biotinylated secondary antibody was detected using Texas Red—streptavidin (Vector Laboratories) or fluorescein isothiocyanate-labeled secondary antibody; stained sections were mounted with 4′,6-diamidino-2-phenylindole containing mounting medium (Vector Laboratories).

Western Blot Analysis

As described previously [15], subconfluent cells were harvested in lysis buffer (10 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% NP-40, 0.1% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 2 mM sodium orthovanadate, protease inhibitor mixture tablet [Roche Molecular Biochemicals, Indianapolis, IN]). Protein concentration was determined with the Bio-Rad protein assay (Bio-Rad, Hercules, CA). The solution was subsequently solubilized in SDS sample buffer containing 10% β-mercaptoethanol. Total protein samples (20 µg) were separated on SDS-PAGE gels of appropriate percentage and transferred to a polyvinylidene difluoride membrane (Immobilon-P; Millipore, Bedford, MA). The membranes were blocked in 5% nonfat milk (Bio-Rad) in 10 mM Tris, 150 mM NaCl (pH 8.0), 0.1% Tween 20 (TBS-T) for 1 hour at room temperature. The membranes were probed with the primary antibody diluted in 5% milk in TBS overnight at 4°C, washed in TBS-Tween 20, incubated with anti-mouse or anti-rabbit HRP-conjugated antibody (Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:3000 in TBS-T for 1 hour at room temperature, and then washed in TBS-T. The signal was visualized using ECL plus (GE Healthcare, Buckinghamshire, UK) and exposed to Kodak X-Omat LS film (Kodak, New York, NY). Experiments were repeated at least twice.

Reagents and Antibodies

Antibodies recognizing Ki-67 (dilution 1:200), fibronectin (dilution 1:1000), and vimentin (dilution 1:500) were purchased from BD Biosciences. α-Smooth muscle actin (α-SMA; 1:500 dilution) and β-actin (1:5000 dilution) were from Sigma (St Louis, MO), and cathepsin B (1:50 for immunofluorescence and 1:5000 for Western blot analysis) was from Athens Research and Technology (Athens, GA). FSP1 antibody (1:200 dilution) was a gift from Dr Eric Neilson (Vanderbilt University). The antibodies, ERK1/2 (p42/44) and phospho-p42/44 mitogen-activated protein kinase (MAPK; pERK1/2), were from Cell Signaling Technology (Danvers, MA). Cathepsin B activity assays (BioVision, Mountain View, CA) were performed as described in the manufacturer's protocol. In brief, cell lysates (data not shown) and conditioned media were incubated with the reaction buffer including substrate for 2 hours at 37°C and, subsequently, were analyzed using a SpectraMax M5 (Molecular Devices, Sunnyvale, CA) plate reader at the Molecular Core Facility, Vanderbilt University. Standardization was based on the number of cells plated in the assay. In addition, each assay contained 0.2 U of active cathepsin B protein as a control (BioVision), which was used to calculate and express the measured cathepsin B activity in the conditioned media samples in “units.”

ELISA

To determine the concentration of secreted human TGFβ1, the DuoSet ELISA kit from R&D Systems (Minneapolis, MN) was used. In brief, conditioned media were activated using 0.1 ml of 1N HCl and then neutralized before addition to 96-well plates prepared with the capture antibody, washed, and blocked with 5% Tween in PBS. The samples and standards were plated in triplicate. After overnight incubation, the plate was washed, and the detection antibody was added followed by incubation with the streptavidin-HRP complex. The developing reaction with substrate was stopped, and the plates were analyzed subsequently. All experiments were repeated at least twice. Data are presented ±SD. Student's t test was performed for statistical analysis.

Results

Coordinated Loss of Ecad and TβRII Results in Increased Invasion

We have shown previously that 70% of esophageal squamous cell cancer tissues harbor concurrent loss of Ecad and TβRII [15]. This led us to hypothesize that abrogation of Ecad-mediated cell adhesion in concert with altered TGFβ signaling results in cell invasion during esophageal tumorigenesis. To test this hypothesis and its biological consequences, we engineered human primary esophageal keratinocytes to express dominant-negative Ecad, EC [15], and dominant-negative mutant TβRII lacking the cytoplasmic tail (ECdnT) and compared them with cells expressing full-length wild-type Ecad or dominant-negative TβRII (dnT) alone. The dominant-negative mutant version of TβRII does not contain the kinase domain [18] and has been shown to induce increased epithelial branching [19] and mammary gland hyperplasia [20,21]. Furthermore, dominant-negative TβRII alters cellular homeostasis [22] and fosters prostrate cancer in a mouse model [23]. We analyzed ECdnT cells for changes in proliferation as well as for their ability to respond to exogenous TGFβ1. Whereas Ecad cells exhibited a slower proliferation rate compared with EC and ECdnT cells, which was diminished further by TGFβ1 stimulation, EC and ECdnT cells did not respond to TGFβ1 (data not shown).

When grown in organotypic culture, in which fibroblasts embedded in Matrigel/collagen form an extracellular matrix with epithelial cells seeded on top, Ecad cells developed a normal epithelium. By contrast, a lack of functional Ecad or TβRII resulted in small areas of invasion by the epithelial cells into the underlying matrix. Dual loss of Ecad and TβRII in these primary esophageal cells led to an increased invasive potential (Figure 1).

Figure 1
ECdnT cells invade into the underlying matrix in organotypic cultures in the presence of fibroblasts. Expression of dominant-negative mutant versions of Ecad and TβRII resulted in cell invasion into the fibroblast-embedded Matrigel/collagen matrix ...

Cathepsin B Up-regulation in ECdnT Cells Mediates Epithelial Cell Invasion

Cathepsin B amplification has been associated with esophageal adenocarcinoma and Barrett esophagus [24,25]. Immunofluorescence staining of an organotypic section with anti-cathepsin B antibody revealed a more intense fluorescence signal for cathepsin B in organotypic cultures of invasive ECdnT cells than control Ecad and EC cells (Figure 2A). To evaluate the correlation between the induction of cathepsin B and the coordinated loss of Ecad and TβRII, we analyzed serial sections of a tissue microarray with normal (n = 4) and squamous cell carcinoma tissues (n = 80 cores from 40 patients). Expression levels of cathepsin B were scored on a scale from 1 to 4, with 1 being absent and 4 having the highest signal intensity (Figure 2B) and compared with previous scoring for Ecad and TβRII expression [15]. Cathepsin B was upregulated in 50 tumor tissues (50/80, 63%) that had loss of both Ecad and TβRII. In 8 tissue cores, the signal for Ecad and TβRII was strong, but cathepsin B expression was lost, whereas the expression pattern of 22 cores demonstrated no correlation. Overall, 58 tissues of 80 or 29 of 40 patients (72%) showed a statistically significant inverse correlation (P = .0013, ρ = -0.34). Representative images of immunofluorescence staining highlighting the inverse correlation for Ecad and cathepsin B are shown in Figure 2B.

Figure 2
Cathepsin B up-regulation inversely correlates with loss of Ecad and TβRII. (A) Cathepsin B (cath B) expression in organotypic cultures is shown by immunofluorescence staining using anti-cathepsin B antibody. The signal intensity was measured ...

A Fibroblast-Secreted Factor Induces Cathepsin B Expression and the Invasive Potential of ECdnT Cells

To analyze the invasive properties of these cells further, Boyden chamber invasion assays were used, revealing that ECdnT cells did not invade (Figure 3A). Whereas cells lacking Ecad, EC, demonstrated an increased invasive potential Boyden chamber assays, ECdnT cells in contrast to their invasive behavior in organotypic cultures did not invade. This result led us to believe that the extracellular matrix or the “tumor environment” may be providing cues to the epithelial compartment for invasion into the matrix to occur.

Figure 3Figure 3
ECdnT cell invasion is mediated by cathepsin B in a fibroblast-dependent manner. (A) Invasion assays using conditioned media from fibroblasts (fibro CM) demonstrated that ECdnT cells gain properties to invade into Matrigel (black bars) compared with unconditioned ...

To address if ECdnT cells could invade in vitro in the presence of a fibroblast-secreted factor, we performed Boyden chamber invasion assays using conditioned media from fibroblasts (Figure 3A) as a chemoattractant. In the presence of conditioned media from fibroblasts, but not unconditioned DMEM (Figure 3A), ECdnT cellls were able to invade through the Matrigel layer.

To analyze the effect of the fibroblast-mediated signaling on cathepsin B expression, we stimulated monolayer Ecad, EC, and ECdnT cells with fibroblast-conditioned medium and compared cathepsin B expression levels by Western blot (Figure 3B). Not only was the expression of cathepsin B increased, but we also observed greater activation of latent cathepsin B in ECdnT cells (Figure 3B). The smaller-molecular weight band corresponds to activated cathepsin B (~30 kDa), and the higher-molecular weight band is recognized as the latent precursor [26].

The up-regulation of cathepsin B has been shown to be regulated by the MAPK pathway. Through analyzing the phosphorylation status of p42/44 in ECdnT cells in response to stimulation with fibroblastconditioned media, we can show that p42/44 is phosphorylated under these conditions (Figure 3C). To demonstrate the importance of the fibroblasts in the induction of cathepsin B, we grew ECdnT cells on the same matrix as in organotypic cultures with and without embedded fibroblasts (Figure 3D). Immunofluorescence staining with anti-cathepsin B antibody shows up-regulation of cathepsin B in ECdnT keratinocytes only when fibroblasts were embedded in the matrix. These data were confirmed in transwell assays in which fibroblasts, fibroblast-conditioned media, or control DMEM was added to the bottom chamber. Again, cathepsin B expression in the ECdnT epithelial cells was only upregulated in the presence of fibroblasts or fibroblast-conditioned media (Figure 3E).

To investigate the involvement of cathepsin B in the fibroblast dependent invasion of ECdnT cells, we infected ECdnT cells with lentivirus encoding short hairpin RNA (shRNA) against cathepsin B and showed a decrease in invasion in Boyden chamber assays (Figure 3F) in the presence of fibroblast-conditioned media. When grown in organotypic cultures, ECdnT cells with suppressed cathepsin B expression invaded less (Figure 3G). Immunofluorescence staining with anti-cathepsin B antibody confirmed the suppression of cathepsin B expression in organotypic cultures (Figure 3G). Therefore, we conclude that the increased invasive behavior of ECdnT cells is on the induction of cathepsin B through a fibroblast-secreted factor.

Fibroblasts Are Activated through Cross Talk with Invasive Epithelial Cells

We performed immunohistochemical staining for several markers associated with fibroblast activation, for example, vimentin, Ki-67, FSP1, and α-SMA (Figure 4A). When stained with anti-vimentin antibody, fibroblasts demonstrated increased expression of vimentin in invasive cultures (Figure 4A). Vimentin-positive fibroblasts localized closely to the areas of epithelial invasion similar to the observation made by Gaggioli et al. [27]. Interestingly, ECdnT keratinocytes also showed a stronger vimentin signal than Ecad and EC cells. Ki-67 staining demonstrated more Ki-67-positive fibroblasts in ECdnT cultures, whereas Ecad organotypic cultures did not induce proliferation of fibroblasts (Figure 4B). The number of FSP1-positive fibroblasts increased in EC and ECdnT organotypic cultures (Figure 4C), whereas fibroblasts in all three organotypic cultures were α-SMA-positive (Figure 4D). The increase in number of FSP1- and vimentin-positive fibroblasts, together with the observed increase in proliferation, indicates activation of these fibroblasts in an invasive environment.

Figure 4
Fibroblasts in the presence of invasive ECdnT cells express markers of activated fibroblasts. A panel of markers detecting activated fibroblasts identifies (A) vimentin-positive, proliferating (B), and FSP1-positive (C) cells in ECdnT organotypic cultures, ...

To evaluate the premise that fibroblasts may be activated through a factor secreted by the epithelial cells, we performed experiments using conditioned media. Treatment with conditioned media from noninvasive cells, for example, Ecad-overexpressing cells versus invasive ECdnT cells, demonstrated the induction of vimentin, α-SMA, and FSP1 in fibroblasts only in the invasive microenvironment (Figure 5A). The suppression of ECdnT cell invasion through infection with shRNA against cathepsin B results in FSP1-negative fibroblasts that are less proliferative (Figure 5B, a and b) and express low levels of vimentin (Figure 5B, c); this is similar to the Ecad control cells in Figure 4A. As in Figure 4A, fibroblasts in the noninvasive environment as well as in the invasive environment are α-SMA-positive (Figure 5B, d). Furthermore, we analyzed fibroblast expression of vimentin and α-SMA grown in monolayer in response to stimulation with TGFβ1, ECdnT-conditioned media, ECdnT-shRNA cathepsin B-conditioned media, and control media to demonstrate the link between fibroblast activation and invasive ECdnT cells. Fibroblasts are vimentin-positive in the presence of TGFβ1 and ECdnT-conditioned media but not in the presence of ECdnT-conditioned media from cells expressing shRNA against cathepsin B or control media. There were no differences in α-SMA expression other than slightly lower levels in fibroblasts stimulated with ECdnT-conditioned medium (Figure 5C).

Figure 5Figure 5
Conditioned medium from ECdnT cultures induces activation and anchorage-independent growth of fibroblasts. (A) Fibroblasts show upregulated levels of vimentin, α-SMA, and FSP1/S100 when stimulated with ECdnT-conditioned medium compared with conditioned ...

Furthermore, we could show that, when grown in soft agar, ECdnT cells were unable to grow in an anchorage-independent fashion (Figure 5D). By contrast, fibroblasts alone, in addition to cocultures of fibroblasts and ECdnT cells, were able to grow in soft agar when stimulated with conditioned media from ECdnT cells or organotypic cultures (Figure 5D).

Cathepsin B and TGFβ1 Are Activated Interdependently

TGFβ1 not only is a key factor in the activation of fibroblasts and known to promote squamous cancer cell invasion [28] but also has been linked to cathepsin B because TGFβ1 activity can be regulated by cathepsin B [29,30]. To investigate the link between the upregulation of cathepsin B and the secretion of TGFβ1 in ECdnT cells, we performed ELISA with conditioned media collected from noninvasive and invasive organotypic cultures. This analysis demonstrates increased levels of TGFβ1 in ECdnT cells, potentially induced to compensate for the disruption of TGFβ signaling through the expression of dominant-negative TβRII (Figure 6A). The levels of TGFβ1 secretion were elevated in monolayer ECdnT cells when grown on collagen (Figure 6B) or after treatment with conditioned media from fibroblast cultures (Figure 6C). This increase correlated with an increase in cathepsin B activity in response to collagen extracellular matrix (Figure 6B, lower panel) or treatment of monolayer ECdnT cells with fibroblast-conditioned medium (Figure 6C, lower panel).

Figure 6
Increased TGFβ1 secretion correlates with cathepsin B activity in ECdnT cells. (A) Conditioned media from organotypic cultures when analyzed by ELISA have statistically significant increased levels of TGFβ1 secretion as determined using ...

Discussion

Esophageal squamous cell cancer patients harbor high mortality rates because of the invasive and metastatic nature of this disease. We demonstrate the importance of the tumor microenvironment in supporting esophageal cell invasion that is mediated through the induction of cathepsin B in the genetic background of mutations in Ecad and TβRII.

Role of Cathepsin B in Cell Invasion

The role of cathepsins in cancer cell invasion has recently drawn attention because of their multiple functions on extracellular matrix remodeling, regulation of protease activation, and cleavage of cell adhesion molecules [31,32]. Elevated levels of cathepsin B have been linked to poor prognosis in lung, breast, head and neck, esophageal adenocarcinoma, colon, and other cancers [24,33,34]. Studies detected increased levels of cathepsin B in aggressive pancreatic tumors [35]. Krueger et al. identified cathepsin B up-regulation to be mediated by the MAPK and p38 signaling pathways using multicellular tumor spheroid cocultures of colon cancer cells, fibroblasts, and monocytic cells [36]. Although we did not detect activation of p38 MAPK, we observed phosphorylation of ERK1/2 (Figure 3B). In vitro studies using Matrigel invasion assays established cathepsin B to be necessary in cell motility and invasion through small interfering RNA and chemical inhibitors [37–40]. Our studies, however, demonstrate that the up-regulation of cathepsin B alone does not confer the ability for increased cell migration but is dependent on the tumor microenvironment.

Mechanisms of Cathepsin B Regulation

The mechanisms of cathepsin B up-regulation are twofold: 1) increased cathepsin B expression as observed in the organotypic model and in the tumor tissues and 2) augmented cathepsin B activity based on posttranslational processing as seen in Western blot analysis after conditioned media transfer. Cathepsin B has been noted to be a target of Hedgehog signaling and is associated with enhanced invasiveness of pancreatic cancer [41]. A model of the tumor microenvironment analyzed the effects of nitric oxide on cathepsin B expression [42], with the finding that cathepsin B is downregulated in response to endothelial nitric oxide synthase and cell invasion is suppressed. Increased levels of cathepsin B have been attributed to changes in TGFβ/BMP signaling, mainly stimulation with TGFβ1 in the presence of Smad1 reduction as has been reported in myeloid tumors [43].

Posttranslational regulation of cathepsin B has centered on the conversion of latent to active cathepsin B protein. A study in glioblastoma showed an increase in cathepsin B activity to be a key regulator of cell invasion using synthetic inhibitors and genetic knock-down approaches [44]. Another mechanism involved in the processing of mature forms of cathepsin B is in the presence of tumor cells in contact with collagen I [45]. In contrast, collagen type II enhances messenger RNA expression of cathepsin B in chondrocytes after induction of protein kinase C and p38 MAPK [46]. Taken together, the mechanisms underlying cathepsin B activation highlight the role of cathepsin B in cancer cell invasion.

Link between Cathepsin B and TGFβ1

We show that the up-regulation of cathepsin B activity correlates with an increase in TGFβ1 concentration in conditioned media of ECdnT cells (Figure 6). The increase in cathepsin B secretion and activity stimulated by collagen has been observed previously [47]. We conclude that the extracellular matrix might aid in the up-regulation of cathepsin B, and cathepsin B, in turn, might increase the levels of activated TGFβ1. Furthermore, the up-regulation of cathepsin B expression and activity induced by fibroblast-conditioned media confirmed the association of cathepsin B and TGFβ1. TGFβ1 is secreted in a latent form and activated through cleavage after secretion, and exocytosis of cathepsin B activates TGFβ1 [30]. In another model system using Leishmania chasagi, TGFβ1 release from the latent complex was dependent on cathepsin B activity [29]. Activated TGFβ1 will then signal to fibroblasts resulting in their activation and the observed epithelial cell invasion.

Fibroblast Activation through ECdnT Cells

The tumor stroma is an important regulator of cancer progression [48,49]. Malignant transformation can be induced in nontumorigenic epithelia through cancer-associated fibroblasts [50,51]. In our study, fibroblasts in organotypic cultures, whether with invasive or noninvasive phenotypes, stained positive for α-SMA. However, the expression of FSP1 and vimentin was increased only in organotypic cultures with more invasive epithelial cells. FSP1 and α-SMA are markers for activated fibroblasts [49]. Furthermore, the expression of FSP1 together with an increase in proliferation as measured by Ki-67 demonstrates that the fibroblasts in coculture with invasive epithelial cells are activated. FSP1 is a lineage marker for fibroblasts and a potential marker for cells undergoing epithelial-mesenchymal transition and acquiring the capacity for increased motility [52,53]. In addition, metastatic carcinoma cells are less likely to form tumors and to metastasize when injected into FSP1./. mice [54]. To restore tumor formation and metastasis, Grum-Schwensen et al. [54] coinjected the carcinoma cells with FSP1+/+ and FSP1-/- fibroblasts, supporting the notion that FSP1-positive fibroblasts are necessary for invasive tumor growth. TGFβ1 can induce the transition from fibroblasts to myofibroblasts and the activation of cancer-associated fibroblasts [49].

Overall, we show here a model of cathepsin B-mediated invasion of epithelial cells induced by cues from activated fibroblasts. This study demonstrates the importance of epithelial-mesenchymal communication and point to secreted factors as the key factors orchestrating the delicate balance between normal and invasive cell fate.

Acknowledgments

The authors thank members of the Beauchamp laboratory, Natasha Deane, Dan Beauchamp, and James Goldenring for discussions. The authors also thank Jalal Hamaamen and Ping Li for technical assistance and Tanner Freeman for patient data analysis.

Abbreviations

TGFβ
transforming growth factor β
Ecad
E-cadherin
EC
dominant-negative E-cadherin
TβRII
TGFβ receptor type II
dnT
dominant-negative TGFβ receptor type II

Footnotes

1C.D.A. is the recipient of a Research Scholar Award from the American Gastroenterology Association/Foundation of Digestive Health and Nutrition and is supported by National Institutes of Health grant DK075379. A.K.R. is supported by the National Institutes of Health/National Cancer Institute for a Program Project in Esophageal Carcinogenesis (PO1-CA098101). The authors thank the Morphology Core and the Molecular Biology Core at the University of Pennsylvania for technical assistance (P30-DK50306 and PO1-CA098101). The authors thank the Immunohistology Core and the Translational Core at Vanderbilt University for sectioning and IHC stainings, and other Core facilities supported through the Digestive Disease Research Center (P30-DK058404) and the Vanderbilt Ingram Cancer Center. The authors have no conflict of interest to declare.

References

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–2252. [PubMed]
2. Okawa T, Michaylira CZ, Kalabis J, Stairs DB, Nakagawa H, Andl CD, Johnstone CN, Klein-Szanto AJ, El-Deiry WS, Cukierman E, et al. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes Dev. 2007;21:2788–2803. [PubMed]
3. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–454. [PubMed]
4. Behrens J, Mareel MM, Van Roy FM, Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol. 1989;108:2435–2447. [PMC free article] [PubMed]
5. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D, Birchmeier W. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol. 1991;113:173–185. [PMC free article] [PubMed]
6. Clevers H. Wnt/β-catenin signaling in development and disease. Cell. 2006;127:469–480. [PubMed]
7. Fagotto F, Funayama N, Gluck U, Gumbiner BM. Binding to cadherins antagonizes the signaling activity of β-catenin during axis formation in Xenopus. J Cell Biol. 1996;132:1105–1114. [PMC free article] [PubMed]
8. Funayama N, Fagotto F, McCrea P, Gumbiner BM. Embryonic axis induction by the armadillo repeat domain of β-catenin: evidence for intracellular signaling. J Cell Biol. 1995;128:959–968. [PMC free article] [PubMed]
9. Heasman J, Crawford A, Goldstone K, Garner-Hamrick P, Gumbiner B, McCrea P, Kintner C, Noro CY, Wylie C. Overexpression of cadherins and underexpression of β-catenin inhibit dorsal mesoderm induction in early Xenopus embryos. Cell. 1994;79:791–803. [PubMed]
10. Bottinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res. 1997;57:5564–5570. [PubMed]
11. Gorska AE, Jensen RA, Shyr Y, Aakre ME, Bhowmick NA, Moses HL. Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-β receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am J Pathol. 2003;163:1539–1549. [PubMed]
12. Forrester E, Chytil A, Bierie B, Aakre M, Gorska AE, Sharif-Afshar AR, Muller WJ, Moses HL. Effect of conditional knockout of the type II TGF-β receptor gene in mammary epithelia on mammary gland development and polyomavirus middle Tantigen induced tumor formation and metastasis. Cancer Res. 2005;65:2296–2302. [PubMed]
13. Wang J, Sun L, Myeroff L, Wang X, Gentry LE, Yang J, Liang J, Zborowska E, Markowitz S, Willson JK, et al. Demonstration that mutation of the type II transforming growth factor β receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem. 1995;270:22044–22049. [PubMed]
14. Turco A, Coppa A, Aloe S, Baccheschi G, Morrone S, Zupi G, Colletta G. Overexpression of transforming growth factor β-type II receptor reduces tumorigenicity and metastastic potential of K-ras-transformed thyroid cells. Int J Cancer. 1999;80:85–91. [PubMed]
15. Andl CD, Fargnoli BB, Okawa T, Bowser M, Takaoka M, Nakagawa H, Klein-Szanto A, Hua X, Herlyn M, Rustgi AK. Coordinated functions of E-cadherin and transforming growth factor β receptor II in vitro and in vivo. Cancer Res. 2006;66:9878–9885. [PMC free article] [PubMed]
16. Andl CD, Mizushima T, Nakagawa H, Oyama K, Harada H, Chruma K, Herlyn M, Rustgi AK. Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem. 2003;278:1824–1830. [PubMed]
17. Hatziapostolou M, Delbe J, Katsoris P, Polytarchou C, Courty J, Papadimitriou E. Heparin affin regulatory peptide is a key player in prostate cancer cell growth and angiogenicity. Prostate. 2005;65:151–158. [PubMed]
18. Serra R, Johnson M, Filvaroff EH, LaBorde J, Sheehan DM, Derynck R, Moses HL. Expression of a truncated, kinase-defective TGF-β type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. J Cell Biol. 1997;139:541–552. [PMC free article] [PubMed]
19. Joseph H, Gorska AE, Sohn P, Moses HL, Serra R. Overexpression of a kinase-deficient transforming growth factor-β type II receptor in mouse mammary stroma results in increased epithelial branching. Mol Biol Cell. 1999;10:1221–1234. [PMC free article] [PubMed]
20. Gorska AE, Joseph H, Derynck R, Moses HL, Serra R. Dominant-negative interference of the transforming growth factor β type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice. Cell Growth Differ. 1998;9:229–238. [PubMed]
21. Bhowmick NA, Zent R, Ghiassi M, McDonnell M, Moses HL. Integrin β1 signaling is necessary for transforming growth factor-β activation of p38MAPK and epithelial plasticity. J Biol Chem. 2001;276:46707–46713. [PubMed]
22. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, Wakefield LM. TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest. 2003;112:1116–1124. [PMC free article] [PubMed]
23. Tu WH, Thomas TZ, Masumori N, Bhowmick NA, Gorska AE, Shyr Y, Kasper S, Case T, Roberts RL, Shappell SB, et al. The loss of TGF-β signaling promotes prostate cancer metastasis. Neoplasia. 2003;5:267–277. [PMC free article] [PubMed]
24. Hughes SJ, Glover TW, Zhu XX, Kuick R, Thoraval D, Orringer MB, Beer DG, Hanash S. A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc Natl Acad Sci USA. 1998;95:12410–12415. [PubMed]
25. Lin L, Aggarwal S, Glover TW, Orringer MB, Hanash S, Beer DG. A minimal critical region of the 8p22-23 amplicon in esophageal adenocarcinomas defined using sequence tagged site-amplification mapping and quantitative polymerase chain reaction includes the GATA-4 gene. Cancer Res. 2000;60:1341–1347. [PubMed]
26. Mort JS, Leduc MS, Recklies AD. Characterization of a latent cysteine proteinase from ascitic fluid as a high molecular weight form of cathepsin B. Biochim Biophys Acta. 1983;755:369–375. [PubMed]
27. Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Harrington K, Sahai E. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol. 2007;9:1392–1400. [PubMed]
28. Lewis MP, Lygoe KA, Nystrom ML, Anderson WP, Speight PM, Marshall JF, Thomas GJ. Tumour-derived TGF-β1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br J Cancer. 2004;90:822–832. [PMC free article] [PubMed]
29. Gantt KR, Schultz-Cherry S, Rodriguez N, Jeronimo SM, Nascimento ET, Goldman TL, Recker TJ, Miller MA, Wilson ME. Activation of TGF-β by Leishmania chagasi: importance for parasite survival in macrophages. J Immunol. 2003;170:2613–2620. [PubMed]
30. Guo M, Mathieu PA, Linebaugh B, Sloane BF, Reiners JJ., Jr Phorbol ester activation of a proteolytic cascade capable of activating latent transforming growth factor-βL a process initiated by the exocytosis of cathepsin B. J Biol Chem. 2002;277:14829–14837. [PubMed]
31. Gocheva V, Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle. 2007;6:60–64. [PubMed]
32. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer. 2006;6:764–775. [PubMed]
33. Campo E, Munoz J, Miquel R, Palacin A, Cardesa A, Sloane BF, Emmert-Buck MR. Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am J Pathol. 1994;145:301–309. [PubMed]
34. Foekens JA, Kos J, Peters HA, Krasovec M, Look MP, Cimerman N, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG. Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol. 1998;16:1013–1021. [PubMed]
35. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D, Joyce JA. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006;20:543–556. [PubMed]
36. Krueger S, Kalinski T, Wolf H, Kellner U, Roessner A. Interactions between human colon carcinoma cells, fibroblasts and monocytic cells in coculture—regulation of cathepsin B expression and invasiveness. Cancer Lett. 2005;223:313–322. [PubMed]
37. Krueger S, Haeckel C, Buehling F, Roessner A. Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line. Cancer Res. 1999;59:6010–6014. [PubMed]
38. Navab R, Mort JS, Brodt P. Inhibition of carcinoma cell invasion and liver metastases formation by the cysteine proteinase inhibitor E-64. Clin Exp Metastasis. 1997;15:121–129. [PubMed]
39. Premzl A, Zavasnik-Bergant V, Turk V, Kos J. Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp Cell Res. 2003;283:206–214. [PubMed]
40. Szpaderska AM, Frankfater A. An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res. 2001;61:3493–3500. [PubMed]
41. Hwang JH, Lee SH, Lee KH, Lee KY, Kim H, Ryu JK, Yoon YB, Kim YT. Cathepsin B is a target of Hedgehog signaling in pancreatic cancer. Cancer Lett. 2009;273:266–272. [PubMed]
42. Decker NK, Abdelmoneim SS, Yaqoob U, Hendrickson H, Hormes J, Bentley M, Pitot H, Urrutia R, Gores GJ, Shah VH. Nitric oxide regulates tumor cell cross-talk with stromal cells in the tumor microenvironment of the liver. Am J Pathol. 2008;173:1002–1012. [PubMed]
43. Reisenauer A, Eickelberg O, Wille A, Heimburg A, Reinhold A, Sloane BF, Welte T, Buhling F. Increased carcinogenic potential of myeloid tumor cells induced by aberrant TGF-β1-signaling and upregulation of cathepsin B. Biol Chem. 2007;388:639–650. [PubMed]
44. Gole B, Duran Alonso MB, Dolenc V, Lah T. Post-translational regulation of cathepsin B, but not of other cysteine cathepsins, contributes to increased glioblastoma cell invasiveness in vitro. Pathol Oncol Res. 2009;15:711–723. [PubMed]
45. Klose A, Wilbrand-Hennes A, Zigrino P, Weber E, Krieg T, Mauch C, Hunzelmann N. Contact of high-invasive, but not low-invasive, melanoma cells to native collagen I induces the release of mature cathepsin B. Int J Cancer. 2006;118:2735–2743. [PubMed]
46. Ruettger A, Schueler S, Mollenhauer JA, Wiederanders B. Cathepsins B, K, and L are regulated by a defined collagen type II peptide via activation of classical protein kinase C and p38 MAP kinase in articular chondrocytes. J Biol Chem. 2008;283:1043–1051. [PubMed]
47. Podgorski I, Linebaugh BE, Sameni M, Jedeszko C, Bhagat S, Cher ML, Sloane BF. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer. Neoplasia. 2005;7:207–223. [PMC free article] [PubMed]
48. De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer. 2008;123:2229–2238. [PubMed]
49. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392–401. [PubMed]
50. Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD, Sudilovsky D, Cunha GR. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res. 2001;61:8135–8142. [PubMed]
51. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999;59:5002–5011. [PubMed]
52. Venkov CD, Link AJ, Jennings JL, Plieth D, Inoue T, Nagai K, Xu C, Dimitrova YN, Rauscher FJ, Neilson EG. A proximal activator of transcription in epithelial-mesenchymal transition. J Clin Invest. 2007;117:482–491. [PMC free article] [PubMed]
53. Xie R, Schlumbrecht MP, Shipley GL, Xie S, Bassett RL, Jr, Broaddus RR. S100A4 mediates endometrial cancer invasion and is a target of TGF-β1 signaling. Lab Invest. 2009;89:937–947. [PMC free article] [PubMed]
54. Grum-Schwensen B, Klingelhofer J, Berg CH, El-Naaman C, Grigorian M, Lukanidin E, Ambartsumian N. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res. 2005;65:3772–3780. [PubMed]

Articles from Neoplasia (New York, N.Y.) are provided here courtesy of Neoplasia Press